ScholarLens Back to search
2004•Diabetes CareOpen access

Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol

Lena Normén, Jiri J Frohlich, Julio S. G. Montaner, Marianne Harris, Tom Elliott, Greg Bondy

Open full text 30 citations

Abstract

A table

Open-access reader

About this research paper

What this paper is about

A table

Why it matters

OpenAlex reports 30 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A table

Key concepts: Fenofibrate, Medicine, Rosiglitazone, Diabetes mellitus, Internal medicine, Cholesterol, Endocrinology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol — Research Paper | ScholarLens